RXDX — Prometheus Biosciences Share News
0.000.00%
HealthcareSpeculativeLarge Cap
- $9.56bn
- $8.85bn
- $6.81m
Roivant rises as analysts upbeat on drugmaker after Merck's deal for rival
Refinitiv Newscasts - U.S. Morning Call: Dollar hits one-month high against yen as traders bet on Fed rate hike
Morning Bid Americas: Banks calm the horses
Prometheus Biosciences soars after Merck's $11 bln buyout
U.S. RESEARCH ROUNDUP-Cepton, Dell Technologies, HP
Press Digest: Wall Street Journal - April 17
Press Digest: Financial Times - April 17
Brief: Merck CEO sees Prometheus drug as multi-billion dollar opportunity
Brief: Merck Strengthens Immunology Pipeline With Acquisition Of Prometheus Biosciences Inc
Merck in late-stage talks to acquire Prometheus Biosciences - WSJ (updated)
Merck in late-stage talks to acquire Prometheus Biosciences -WSJ
Brief: Merck In Late-Stage Talks To Acquire Prometheus Biosciences - WSJ
Brief: Prometheus Biosciences Does Not Hold Any Deposits At SVB
Brief: Prometheus Biosciences Q4 cash & investments USD 695.8 million
Brief: Prometheus Biosciences Reports Q4 And FY 2022 Financial Results And Highlights Recent Corporate Progress
U.S. RESEARCH ROUNDUP- Accenture, Box, Vail Resorts
Dated alert on Prometheus Biosciences filing for stock offering withdrawn
Brief: Prometheus Biosciences Announces Pricing Of Public Upsized $500 Million Offering Of Common Stock
U.S. RESEARCH ROUNDUP- Churchill Downs, Mirati Therapeutics, Vivint Smart Home